These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35941008)
1. Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy. Mandoorah Q; Benamran D; Pinar U; Seisen T; Abdessater M; Iselin C; Rouprêt M Prog Urol; 2022 Dec; 32(16):1462-1468. PubMed ID: 35941008 [TBL] [Abstract][Full Text] [Related]
2. Single Positive Lymph Node Prostate Cancer Can Be Treated Surgically without Recurrence. Kim DK; Koo KC; Abdel Raheem A; Kim KH; Chung BH; Choi YD; Rha KH PLoS One; 2016; 11(3):e0152391. PubMed ID: 27031340 [TBL] [Abstract][Full Text] [Related]
3. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. Özsoy M; D'Andrea D; Moschini M; Foerster B; Abufaraj M; Mathieu R; Briganti A; Karakiewicz PI; Roupret M; Seitz C; Czech AK; Susani M; Shariat SF Urol Oncol; 2018 Apr; 36(4):158.e1-158.e6. PubMed ID: 29288003 [TBL] [Abstract][Full Text] [Related]
4. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. Schiavina R; Manferrari F; Garofalo M; Bertaccini A; Vagnoni V; Guidi M; Borghesi M; Baccos A; Morselli-Labate AM; Concetti S; Martorana G BJU Int; 2011 Oct; 108(8):1262-8. PubMed ID: 21446934 [TBL] [Abstract][Full Text] [Related]
5. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Kupelian PA; Katcher J; Levin HS; Klein EA Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811 [TBL] [Abstract][Full Text] [Related]
6. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins. Aoun F; Albisinni S; Henriet B; Tombal B; Van Velthoven R; Roumeguère T Scand J Urol; 2017 Feb; 51(1):20-26. PubMed ID: 27910728 [TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441 [TBL] [Abstract][Full Text] [Related]
8. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer. Morizane S; Honda M; Shimizu R; Teraoka S; Nishikawa R; Tsounapi P; Kimura Y; Iwamoto H; Hikita K; Takenaka A Int J Clin Oncol; 2020 Jul; 25(7):1398-1404. PubMed ID: 32333202 [TBL] [Abstract][Full Text] [Related]
9. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833 [TBL] [Abstract][Full Text] [Related]
10. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
11. Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies). Brureau L; Emeville E; Multigner L; Blanchet P Prog Urol; 2018 Jun; 28(8-9):442-449. PubMed ID: 29789237 [TBL] [Abstract][Full Text] [Related]
12. Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients. Berchiche W; Long Depaquit T; Baboudjian M; Barret É; Rozet F; Cathelineau X; Bastide C Prog Urol; 2023 Aug; 33(8-9):437-445. PubMed ID: 37248105 [TBL] [Abstract][Full Text] [Related]
13. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients. Schiavina R; Bertaccini A; Franceschelli A; Manferrari F; Vagnoni V; Borghesi M; Morselli-Labate AM; Martorana G Anticancer Res; 2010 Jun; 30(6):2297-302. PubMed ID: 20651383 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Da Pozzo LF; Cozzarini C; Briganti A; Suardi N; Salonia A; Bertini R; Gallina A; Bianchi M; Fantini GV; Bolognesi A; Fazio F; Montorsi F; Rigatti P Eur Urol; 2009 May; 55(5):1003-11. PubMed ID: 19211184 [TBL] [Abstract][Full Text] [Related]
16. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml. Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425 [TBL] [Abstract][Full Text] [Related]
17. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? Kluth LA; Xylinas E; Rieken M; Chun FK; Fajkovic H; Becker A; Karakiewicz PI; Passoni N; Herman M; Lotan Y; Seitz C; Schramek P; Remzi M; Loidl W; Guillonneau B; Rouprêt M; Briganti A; Scherr DS; Graefen M; Tewari AK; Shariat SF Urol Oncol; 2014 Jan; 32(1):47.e1-8. PubMed ID: 24055425 [TBL] [Abstract][Full Text] [Related]
18. Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy. Pagano MJ; Whalen MJ; Paulucci DJ; Reddy BN; Matulay JT; Rothberg M; Scarberry K; Patel T; Shapiro EY; RoyChoudhury A; McKiernan J; Benson MC; Badani KK Prostate; 2016 Feb; 76(2):226-34. PubMed ID: 26481325 [TBL] [Abstract][Full Text] [Related]
19. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Briganti A; Joniau S; Gandaglia G; Cozzarini C; Sun M; Tombal B; Haustermans K; Hinkelbein W; Shariat SF; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):960-7. PubMed ID: 24351411 [TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Touijer KA; Mazzola CR; Sjoberg DD; Scardino PT; Eastham JA Eur Urol; 2014 Jan; 65(1):20-5. PubMed ID: 23619390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]